Effect of Vitamin E on Clinical Outcomes in Patients With Non-alcoholic Fatty Liver Disease: A Meta-Analysis.
| Autor: | Karedath J; Internal Medicine, The James Cook University Hospital, Middlesbrough, GBR., Javed H; Medical School, Dow International Medical College, Karachi, PAK., Ahsan Talpur F; Medical School, Dow International Medical College, Karachi, PAK., Lal B; Medical School, Chandka Medical College, Larkana, PAK., Kumari A; Medicine, Chandka Medical College, Larkana, PAK., Kivan H; Medical School, Ondokuz Mayıs University, Samsun, TUR., Anirudh Chunchu V; Medical School, Avalon University School of Medicine, Willemstad, CUW., Hirani S; Cardiology, Baqai Hospital, Karachi, PAK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Dec 21; Vol. 14 (12), pp. e32764. Date of Electronic Publication: 2022 Dec 21 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.32764 |
| Abstrakt: | The aim of the current meta-analysis was to assess the effects of vitamin E on clinical outcomes in individuals with non-alcoholic fatty liver disease (NAFLD). The current meta-analysis was planned, reported, and conducted per the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Two authors systematically searched for all papers using PubMed, Cochrane Central Register, and Embase from inception to October 15, 2022. Outcomes assessed in the current meta-analysis included changes in alanine transaminase (ALT) and aspartate transaminase (AST) from baseline in IU/L. Other outcomes included a change in BMI (kg/cm2), a change in total cholesterol level from baseline (mg/l), and a fibrosis score. Total articles were included in the current meta-analysis, enrolling 569 patients (274 patients in the vitamin E group and 295 in the placebo group). The study found that reduction in ALT levels, AST levels, and BMI was significantly greater in patients in the vitamin E group compared to the placebo group. However, no significant differences were reported in terms of change in fibrosis score and total cholesterol. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Karedath et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|